Tyr406
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr406  -  TR-beta1 (human)

Site Information
FLLAFEHyINYRKHH   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 976541

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 2 ) , mutation of modification site ( 1 , 2 ) , phospho-antibody ( 1 ) , western blotting ( 1 , 2 )
Disease tissue studied:
breast cancer ( 2 ) , breast adenocarcinoma ( 2 ) , breast cancer, triple negative ( 2 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
Src (human) ( 2 )
Kinases, in vitro:
Src (human) ( 2 )
Treatments:
liothyronine ( 2 ) , SKI-606 ( 2 )

Downstream Regulation
Effects of modification on TR-beta1:
activity, induced ( 2 ) , protein degradation ( 1 , 2 )
Effects of modification on biological processes:
carcinogenesis, inhibited ( 1 , 2 ) , cell growth, inhibited ( 1 , 2 ) , signaling pathway regulation ( 2 )

References 

1

Park JW, Zhao L, Willingham MC, Cheng SY (2017) Loss of tyrosine phosphorylation at Y406 abrogates the tumor suppressor functions of the thyroid hormone receptor β. Mol Carcinog 56, 489-498
27254276   Curated Info

2

Park JW, Zhao L, Webb P, Cheng SY (2014) Src-dependent phosphorylation at Y406 on the thyroid hormone receptor β confers the tumor suppressor activity. Oncotarget 5, 10002-16
25275301   Curated Info